Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
NATO
Artificial Intelligence
NBA
World Cup
Social Media
Stock Markets
Infrastructure
Donald Trump
War
Basketball
South America
Education
Published • loading... • Updated

Sulopenem Is Noninferior to Amoxicillin/Clavulanate For Uncomplicated UTIs

Summary by contagionlive.com
Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections (uUTIs), and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.

2 Articles

All
Left
Center
Right
contagionlive.comcontagionlive.com

Sulopenem is Noninferior to Amoxicillin/Clavulanate For Uncomplicated UTIs

Marketed as Orlynvah, oral sulopenem from Iterum Therapeutics was FDA approved last fall for uncomplicated urinary tract infections (uUTIs), and has shown efficacy against infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis.

Read Full Article
contemporaryobgyn.netcontemporaryobgyn.net

Oral sulopenem demonstrates non-inferiority to amoxicillin/clavulanate in phase 3 uUTI trial

Oral sulopenem (ORLYNVAH; Iterum Therapeutics) was non-inferior to amoxicillin/clavulanate for treating uUTIs in women, per the phase 3 REASSURE trial.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contemporaryobgyn.net broke the news in on Wednesday, June 25, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

UTI icon

UTI

United States icon

United States

News
For You
SearchBlindspotLocal